Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 673 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma January 25, 2021 Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... November 30, 2021 New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines July 15, 2020 FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma October 27, 2025 Load more HOT NEWS Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... NHS lung cancer patients in England to get early access to... Woman Helps Students With Special Needs Achieve Success After Graduation
